Heart failure & cardiomyopathies
Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis
Authors' conclusion
Our study did not find sufficient statistical evidence regarding combination therapy with BB and ACEi/ARBs in reduction of TTS recurrence.
Study context
- Population
- Patients with Takotsubo syndrome receiving medical therapy with beta-blockers (BB), ACEi/ARBs; studies published January 2010–September 2022
- Participants
- 3,407 patients · 6 clinical studies
- Comparison
- BB and/or ACEi/ARBs vs control
- Outcome
- TTS recurrence
Pooled result
As reported in the abstract
TTS recurrence · 40±10 months follow-up
Odds ratio (95% CI)P value
ACEi/ARBs vs Control
0.83(0.47–1.47)
P = 0.52BB vs Control
1.01(0.63–1.61)
P = 0.96ACEi/ARBs vs BB
0.88(0.51–1.53)
P = 0.65BB + ACEi/ARBs vs Control
0.91(0.58–1.43)
P = 0.68BB + ACEi/ARBs vs ACEi/ARBs
0.79(0.46–1.34)
P = 0.38BB + ACEi/ARBs vs BB
0.77(0.49–1.21)
P = 0.26- Overall TTS recurrence
- 160 (4.7%) out of 3407
Original publication
Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis. Heart. Published 4 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it